BriaCell gains on partnership with ImaginAb
19/08/2021 13:49
** Shares of biotechnology firm BCTX.O up 7.9% premarket
at $6.15
** Announces a multi-year, non-exclusive license agreement
with ImaginAb to evaluate immunotherapy imaging technology in
advanced breast cancer urn:newsml:reuters.com:*:nGNX28VnJQ
** ImaginAb to supply clinical doses of its ImmunoPET
technology for use in BriaCell's ongoing study in metastatic or
locally recurrent breast cancer patients under the deal
** ImaginAb will receive license fees and payments for
providing ongoing technical, clinical and regulatory support
** Up to Wednesday's close, BCT has gained 19.4% YTD
(Reporting by Shashank Nayar in Bengaluru)
((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study